Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance
Shaista Hafeez, Amanda Webster, Vibeke N Hansen, Helen A McNair, Karole Warren-Oseni, Emma Patel, Ananya Choudhury, Joanne Creswell, Farshad Foroudi, Ann Henry, Tomas Kron, Duncan B McLaren, Anita Mitra, Hugh Mostafid, Daniel Saunders, Elizabeth Miles, Clare Griffin, Rebecca Lewis, Emma Hall, Robert Huddart
BMJ Open | BMJ PUBLISHING GROUP | Published : 2020
INTRODUCTION: Daily radiotherapy delivered with radiosensitisation offers patients with muscle invasive bladder cancer (MIBC) comparable outcomes to cystectomy with functional organ preservation. Most recurrences following radiotherapy occur within the bladder. Increasing the delivered radiotherapy dose to the tumour may further improve local control. Developments in image-guided radiotherapy have allowed bladder tumour-focused 'plan of the day' radiotherapy delivery. We aim to test within a randomised multicentre phase II trial whether this technique will enable dose escalation with acceptable rates of toxicity. METHODS AND ANALYSIS: Patients with T2-T4aN0M0 unifocal MIBC will be randomised..View full abstract
Awarded by Cancer Research UK
Awarded by Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU)
The RAIDER trial is funded by Cancer Research UK (CRUK/14/016) with programme grants to support the work of the Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU) (grant number C1491/A15955).